FFA
NBIX icon

Frazier Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Frazier Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.8K Hold
70
– – 0.01% 371
2026
Q1 		$9.22K Hold
70
– – 0.01% 423
2025
Q4 		$9.93K Hold
70
– – 0.01% 359
2025
Q3 		$9.83K Hold
70
– – 0.01% 355
2025
Q2 		$8.8K Hold
70
– – 0.01% 367
2025
Q1 		$7.74K Hold
70
– – 0.01% 370
2024
Q4 		$9.6K Hold
70
– – 0.01% 347
2024
Q3 		$8.07K Hold
70
– – 0.01% 416
2024
Q2 		$9.64K Hold
70
– – 0.01% 447
2024
Q1 		$9.65K Hold
70
– – 0.01% 419
2023
Q4 		$9.22K Buy
+70
New +$8.06K 0.01% 362

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Frazier Financial Advisors's NBIX Position: Q2 2026 in Review

Frazier Financial Advisors held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 70 shares worth $11.8K. The position accounts for 0.01% of the portfolio, ranked #371.

Frazier Financial Advisors first reported a position in NBIX in Q4 2023 and has held it in 11 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Frazier Financial Advisors held 70 shares of Neurocrine Biosciences worth $11.8K as of Q2 2026.
  • Frazier Financial Advisors left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up 0.01% of Frazier Financial Advisors's portfolio in Q2 2026, its #371 holding.
  • Frazier Financial Advisors first reported a position in Neurocrine Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Frazier Financial Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.